Live Cell Encapsulation Market

Encapsulated cell-based products are increasingly being investigated across a myriad of clinical applications, potentially overcoming a number of barriers associated with conventional treatment options

-- Chief Scientist, an Israel based small-sized company

Live Cell Encapsulation Market Overview

The live cell encapsulation market is estimated to be worth $81 million in 2019 and is expected to grow at CAGR of 21% during the forecast period. Chronic disorders, such as diabetes, cancer, heart disease, obesity, and certain types of mental health problems, are considered among the leading causes of death and disability across the globe. According to a report published by the Center for Managing Chronic Disease at the University of Michigan in 2018, more than 50% of the global population lives with some form of chronic illness. In 2018, the global prevalence of diabetes (considered to be one of the fastest-growing clinical conditions) was estimated to be around 425 million; likewise, around 450 million people worldwide are suffering from some form of mental health problem and / or neurological disorder. In addition, the World Health Organization (WHO) reported that different forms of cancers account for about 0.6 million deaths annually in the US alone. Over the years, advances in cell biology and regenerative medicine have led to the development of various cell-based therapies, which claim to possess the potential to address several unmet needs related to the treatment of different chronic clinical conditions. In fact, experts believe that mesenchymal stem cells may have the potential to improve patients' resistance to the ongoing novel COVID-19 infections. However, there are certain evident challenges, such as scarcity of viable donors, inherent immunogenicity, complications related to supply of oxygen / essential nutrients to grafted cells, drug delivery limitations, and the need for frequent re-administration of cells, which have so far restricted the use of cell-based interventions.

Extensive research on cell encapsulation strategies have enabled the development of a variety of technologies capable of confining therapeutic entities within biocompatible matrices / carriers. Encapsulated therapy products offer a myriad of advantages, and have been shown to be capable of addressing existing concerns related to cell sourcing, obviating the need for complex surgical procedures, and enabling targeted drug delivery without the need for immunosuppressive follow-on regimens. In fact, since 2013, over 3,000 patents have been published related to the aforementioned type of therapy, indicating the rapid pace of R&D activities in live cell encapsulation market. Stakeholders have also received significant support from both private and public investors. However, the commercial success of such products is still dependent on ongoing clinical studies, as no such therapy has yet been approved.

Recent Developments in Live Cell Encapsulation Market:

Several recent developments have taken place in the field of live cell encapsulation market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

• In August 2023, Verde Technologies entered into a collaboration with Northern Illinois University and National Renewable Energy Laboratory with an aim to commercialize encapsulation of perovskite solar cells. 
• In March 2023, Vertex announced the FDA clearance of investigational new drug application for VX-264, a novel encapsulated cell therapy for the treatment of type 1 diabetes.

Key Companies in Live Cell Encapsulation Market 

Examples of key encapsulation companies engaged in live cell encapsulation market (which have also been profiled in this market report; the complete list of encapsulation companies is available in the full report) include Beta-O2 Technologies, Diatranz Otsuka, Sernova, ViaCyte, Betalin Therapeutics, Defymed, Kadimastem, Seraxis, Azellon Cell Therapeutics, EryDel, Erytech Pharma, Gloriana Therapeutics, Living Cell Technologies, MaxiVAX, Neurotech Pharmaceuticals, PharmaCyte Biotech and Sernova. This market report includes an easily searchable excel database of all the encapsulation companies providing live cell encapsulation therapeutics and technologies, worldwide.

Scope of the Report

The ‘Live Cell Encapsulation Market: Focus on Therapeutics and Technologies, 2019-2030’ market report features an extensive study of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the live cell encapsulation market. It is worth mentioning that the market research report also provides insights on therapy products wherein other active drug substances have been encapsulated within living cells.

Amongst other elements, the market research report features:

• A detailed assessment of the current market landscape of encapsulated cell therapies and affiliated technologies, highlighting various target disease indications, phase of development, encapsulation method, type of cells / API, and route of administration, along with information on various stakeholder companies that are developing novel encapsulation methods / techniques for use in storage and transportation of cells, as well as other applications. 
• Comprehensive profiles of industry players that are currently engaged in the preclinical / clinical development of their proprietary encapsulated cell therapies, featuring an overview of the company, its financial information (if available), and a detailed description of its product(s), highlighting mechanism of action, current development status, and key preclinical / clinical trial results. Each profile also includes a list of recent developments, highlighting the key milestones achieved, partnership activity, and the likely strategies that may be adopted by these players to fuel growth in the in the foreseen future.
• An in-depth analysis of the patents that have been published related to cell encapsulation technologies, since 2013. The analysis also highlights the key trends associated with these patents, across patent type, regional applicability, CPC classification, emerging focus areas, leading industry players (in terms of number of patents filed / granted), and current intellectual property-related benchmarks and valuation.
• A comprehensive clinical trial analysis of completed, ongoing and planned studies of various encapsulated cell therapies. The analysis highlights the key trends associated with these clinical studies across various parameters, such as trial start year, trial status, phase of development, leading industry and non-industry players (in terms of number of trials conducted), study design, target therapeutic area, key indications, study focus, clinical endpoints, and enrolled patient population and regional distribution of trials.
• An analysis of the partnerships that have been established in live cell encapsulation market in the period 2013-2018, covering R&D collaborations, licensing agreements, mergers and acquisitions, product development and / or commercialization agreements, manufacturing agreements, clinical trial agreements, process development agreements, and other relevant deals.
• An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings received by companies that are focused in this area. The market research report also features a detailed study on the various grants that have been awarded to research institutes in live cell encapsulation market.
• An analysis highlighting potential strategic partners (for instance, manufacturers) for encapsulated therapy developers based on multiple parameters, such as therapeutic focus overlap, cell type overlap, research programs, existing collaborations, and developer strength

The key objective of live cell encapsulation market report is to provide a detailed market analysis in order to estimate the existing market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunity for live cell encapsulation market during the forecast period. Based on likely licensing deal structures and agreements that are expected to be signed in the foreseen future, we have provided an informed estimate on the likely evolution of the market for the forecast period 2019-2030. In addition, we have provided information on (potential) sales-based revenues generated by encapsulated cell therapies that are currently in late stages of development for the treatment of different chronic disorders, based on parameters, such as target consumer segments, likely adoption rates and expected pricing. The market report features likely distribution of the current and forecasted opportunity across [A] different therapeutic areas (eye disorders, metabolic disorders, neurological disorders, and oncological disorders), [B] target disease indications (ataxia telangiectasia, breast cancer, diabetes, glaucoma, head and neck cancer, macular telangectasia, pancreatic cancer, Parkinson's disease, and retinitis pigmentosa), [C] type of encapsulation material used (alginate-based microcapsules, cellulose hydrogels, medical-grade plastics, and red blood cells), and [D] key geographical regions (North America, Europe and Asia Pacific). To account for the uncertainties associated with the development of novel therapy products and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution. 

The opinions and insights presented in this market research report were influenced by discussions conducted with several stakeholders in live cell encapsulation market. The market report features detailed transcripts of interviews held with the following individuals:

• Alexander Scheer (Chief Scientific Officer, Erytech Pharma)
• Manuel Pires (Business Developer, Defymed)
• Michel Revel (Chief Scientist, Kadimastem) and Galit Mazooz-Perlmuter (Business Development Manager, Kadimastem)
• Mick McLean (Chief Executive Officer, Atelerix)
• Quinton Oswald (Former President and Chief Executive Officer, Neurotech Pharmaceuticals)
• William L Rust (Founder and Chief Executive Officer, Seraxis)
• Yuval Avni (Former Chief Executive Officer, Beta-O2 Technologies)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What is live cell encapsulation?

Answer: Live cell encapsulation refers to the process of enveloping living cells inside a protective matrix or structure.

Question 2: How big is the live cell encapsulation market?

Answer: The live cell encapsulation market size is estimated to be worth $81 million in 2019.

Question 3: What is the projected market growth of the live cell encapsulation market?

Answer: The live cell encapsulation market is expected to grow at compounded annual growth rate (CAGR) of over 21% during the forecast period 2019 - 2030.

Question 4: Who are the leading players in the live cell encapsulation market?

Answer: Examples of key companies engaged in live cell encapsulation market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Beta-O2 Technologies, Diatranz Otsuka, Sernova, ViaCyte, Betalin Therapeutics, Defymed, Kadimastem, Seraxis, Azellon Cell Therapeutics, EryDel, Erytech Pharma, Gloriana Therapeutics, Living Cell Technologies, MaxiVAX, Neurotech Pharmaceuticals, PharmaCyte Biotech and Sernova.

Question 5: How many patents related to the live cell encapsulation have been filed till date?

Answer: Till date, over 3,000 patents related to the live cell encapsulation have been filed, indicating the heightened pace of innovation in the industry.

Question 6: How many partnership deals have been inked between the companies engaged in the live cell encapsulation market?

Answer: Since 2013, more than 150 partnership deals have been inked between the players engaged in live cell encapsulation market, indicating the consolidation efforts of stakeholders in the industry.

Question 7: How much money has been invested by stakeholders in the live cell encapsulation market?

Answer: Over USD 1 billion has been invested by stakeholders in the live cell encapsulation market, highlighting the growing opportunities within the industry.